Tonapofylline: a selective adenosine-1 receptor antagonist for the treatment of heart failure

Bibliography

• Hunt SA, Abraham WT, Chin MH, ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult-summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing committee to update the 2001 guidelines for the evaluation and management of heart failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005;112:1825-52
   Web of Science ®Google Scholar
• Rosamond W, Flegal K, Furie K, Heart disease and stroke statistics-2008 update: a report from the American Heart Association statistics committee and stroke statistics committee. Circulation 2008;117:e25-146
   PubMed Web of Science ®Google Scholar
• Pitt B, Zannad F, Remme WJ, The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17
   PubMed Web of Science ®Google Scholar
• Pitt B, Remme W, Zannad F, Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21
   PubMed Web of Science ®Google Scholar
• Poole-Wilson PA, Swedberg K, Cleland JGF, Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the carvedilol or metoprolol european trial: (COMET): randomized controlled trial. Lancet 2003;362:7-13
   PubMed Web of Science ®Google Scholar
• MERIT-HF study group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/AL randomized intervention trial in congestive heart failure (MERIT-HF). Lancet 1999;353:2001-7
   PubMed Web of Science ®Google Scholar
• Ronco C, Haapio M, House AA, Cardiorenal syndrome. J Am Coll Cardiol 2008;52:1527-39
   PubMed Web of Science ®Google Scholar
• Schrier RW. Cardiorenal versus renocardiac syndrome: is there a difference? Nat Clin Pract Nephrol 2007;3:637
   PubMedGoogle Scholar
• Ronco C, House AA, Haapio M. Cardiorenal syndrome: refining the definition of a complex symbiosis gone wrong. Intensive Care Med 2008;34:957-62
   PubMed Web of Science ®Google Scholar
• Dries DL, Exner DV, Domanski MJ, The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2000;35:681-9
   PubMed Web of Science ®Google Scholar
• Hillege HL, Nitsch D, Pfeffer MA, Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 2006;113:671-8
   PubMed Web of Science ®Google Scholar
• Fonarow GC, Adams KF, Abraham WT, Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA 2005;293:32-40G
   Web of Science ®Google Scholar
• Jessup M, Abraham WT, Casey DE, 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology foundation/American Heart Association task force on practice guidelines. Circulation 2009;119:1977-2016
   PubMed Web of Science ®Google Scholar
• Adams KF, Lindenfeld J, Arnold JMO, HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Card Fail 2006;12:e1-122
   PubMed Web of Science ®Google Scholar
• Lauschke A, Teichgraber UK, Frei U, Low-dose dopamine worsens renal perfusion in patients with acute renal failure. Kidney Int 2006;69:1669-74
   PubMed Web of Science ®Google Scholar
• Costanzo MR, Guglin ME, Saltzberg MT, Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2007;49:675-83
   PubMed Web of Science ®Google Scholar
• Szabo T, Felger D, von Haehling S, Overview of emerging pharmacotherapy in chronic heart failure. Expert Opin Pharmacother 2009;10:2055-74
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Gattis WA, O'Connor CM, Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004;291:1963-71
   PubMed Web of Science ®Google Scholar
• Goldsmith SR, Elkayam U, Haught WH, Efficacy and safety of the vasopressin V1A/V2-receptor antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilot study. J Card Fail 2008;14:641-7
   PubMed Web of Science ®Google Scholar
• Slawsky MT, Givertz MM. Rolofylline: a selective adenosine 1 receptor antagonist for the treatment of heart failure. Expert Opin Pharmacother 2009;10:311-22
   PubMed Web of Science ®Google Scholar
• Gottlieb SS. Adenosine A1 antagonists and the cardiorenal syndrome. Curr Heart Fail Rep 2008;5:105-9
   PubMedGoogle Scholar
• Shah RH, Frishman WH. Adenosine1 receptor antagonism. A new therapeutic approach for the treatment of decompensated heart failure. Cardiol Rev 2009;17:125-31
   PubMed Web of Science ®Google Scholar
• Kuan CJ, Herzer WA, Jackson EK. An experimental paradigm for investigating the role of endogenous adenosine/A1 receptor interactions in vivo. J Pharmacol Exp Ther 1992;263:657-62
   PubMed Web of Science ®Google Scholar
• Vu C, Kiesman WF, Conlon PR, Tricyclic imidazoline derivatives as potent and selective adenosine A1 receptor antagonists. J Med Chem 2006;49:7132-9
   PubMed Web of Science ®Google Scholar
• Kiesman WF, Zhao J, Conlon PR, Potent and orally bioavailable 8-bicyclo[2.2.2]octylxanthines as adenosine a1 receptor antagonists. J Med Chem 2006;49:7119-31
   PubMed Web of Science ®Google Scholar
• Vitzhum H, Weiss B, Bachleitner W, Gene expression of adenosine receptors along the nephron. Kidney Int 2004;65:1180-90
   PubMed Web of Science ®Google Scholar
• Doggrell SA. BG-9928. Curr Opin Invest Drug 2005;6:962-8
   PubMedGoogle Scholar
• Ticho B, Whalley E, Gill A, Renal effects of BG9928, an A1 adenosine receptor antagonist, in rats and nonhuman primates. Drug Dev Res 2003;58:486-92
   Web of Science ®Google Scholar
• Acuhampach JA, Jin X, Moore J, Comparison of three different A1 adenosine receptor antagonists on the infarct size and multiple cycle ischemic preconditioning in anesthetized dogs. J Pharmacol Exp Ther 2004;308:846-56
   PubMed Web of Science ®Google Scholar
• Kuan CJ, Herzer WA, Jackson EK. Cardiovascular and renal effects of blocking A1 adenosine receptors. J Cardiovasc Pharmacol 1993;21:822-8
   PubMed Web of Science ®Google Scholar
• Gellai M, Schreiner FG, Ruffolo RR, CVT-124, a novel adenosine A1 receptor antagonist with unique diuretic activity. J Pharmacol Exp Ther 1998;286:1191-6
   PubMed Web of Science ®Google Scholar
• Wilcox CS, Welch WJ, Schreiner GF, Natriuretic and diuretic actions of a highly selective adenosine A1 receptor antagonist. J Am Soc Nephrol 1999;10:714-20
   PubMed Web of Science ®Google Scholar
• Yang JN, Chen JF, Fredholm BB. Physiological roles of A1 and A2A adenosine receptors in regulating heart rate, body temperature, and locomotion as revealed using knockout mice and caffeine. Am J Physiol Heart Circ Physiol 2009;296:H1141-9
   PubMed Web of Science ®Google Scholar
• Lucas DG, Hendrick JW, Sample JA, Cardiorenal effects of adenosine subtype 1 (A1) receptor inhibition in an experimental model of heart failure. J Am Coll Surg 2002;194:603-9
   PubMed Web of Science ®Google Scholar
• Mitrovic V, Seferovic P, Dodic S, Cardio-renal effects of the A1 adenosine receptor antagonist SLV-320 in patients with heart failure. Circ Heart Fail 2009;2:523-31
   PubMed Web of Science ®Google Scholar
• Pfister JR, Belardinelli L, Lee G, Synthesis and biological evaluation of the enantiomers of the potent and selective A1-adenosine antagonist 1,3-dipropyl-8-[2-(5,6-epoxynorbonyl)]-xanthine. J Med Chem 1997;40:1773-8
   PubMed Web of Science ®Google Scholar
• Rotella D. Adenosine receptor symposium. American chemical society. Boston: IDDB meeting report; 2002
   Google Scholar
• Li ZM, Tao Y, Korter K, TenHoor CCS. Cross-species metabolism profiling of BG9928, a potent antagonist of adenosine A1 receptor [abstract 272]. Drug Metab Rev 2004;36:S1
   Web of Science ®Google Scholar
• Ticho B, Marbury T, Zhu Y, Renal effects of BG9928, an A1 adenosine antagonist, in rats and healthy human subjects. Drug Dev Res 2003;56:556
   Web of Science ®Google Scholar
• Greenberg B, Thomas I, Banish D, Effects of multiple oral doses of an A1 adenosine antagonist, BG9928, in patients with heart failure. J Am Coll Cardiol 2007;50:600-6
   PubMed Web of Science ®Google Scholar
• Nieminen M, Chertow G, Deykin A, Phase 2b study to assess the safety and tolerability of IV tonapofylline in subjects with acute decompensated heart failure (ADHF) and renal insufficiency (TRIDENT-1). Presented at the European Society of Cardiology Heart Failure Congress; 30 May 2010; Berlin, Germany
   Google Scholar
• Gottlieb SS, Ticho B, Deykin A, The effects of BG9928, an adenosine A1 receptor antagonist, in patients with congestive heart failure. J Clin Pharmacol 2010; In press
   PubMed Web of Science ®Google Scholar
• Gottleib SS, Skettino SL, Wolff A, Effects of BG9719 (CVT-124), an A1-adenosine receptor antagonist, and furosemide on glomerular filtration rate and natriuresis in patients with congestive heart failure. J Am Coll Cardiol 2000;35:56-9
   PubMed Web of Science ®Google Scholar
• Giverz MM, Massie BM, Fields TK, The effects of KW-3902, an adenosine A1-receptor antagonist, on acute decompensated heart failure and renal impairment or diuretic resistance. J Am Coll Cardiol 2007;50:1551-60
   PubMed Web of Science ®Google Scholar